What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?
Glenn D. Prestwich(University of Utah), David J. McQuillan(Research Triangle Park Foundation), William E. Tente(Research Triangle Park Foundation), Christopher K. Breuer(Nationwide Children's Hospital), Sangeeta N. Bhatia(Broad Institute), Richard McFarland(Center for Biologics Evaluation and Research), Jeffrey Schox(Public Library of Science), Chris Mason(Oak Ridge National Laboratory), Jonathan Sackner‐Bernstein(Neostem (United States)), Shannon L. M. Dahl(Research Triangle Park Foundation)
Cited by 62
Related Papers
Microfluidic organs-on-chips
|Nature Biotechnology|2014|3.2k
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
|PLoS Pathogens|2016|451
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276